IDegLira improves patient-reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal-bolus therapy
| Autor: | Mattis F. Ranthe, Petra Őrsy, Danny H. Sugimoto, Randi Grøn, Eden Miller, Ankur Doshi, Adie Viljoen, Nikolaos Tentolouris, Esteban Jódar, Liana K. Billings |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Insulin degludec
medicine.medical_specialty Endocrinology Diabetes and Metabolism Enfermedad cardiovascular 030209 endocrinology & metabolism 030204 cardiovascular system & hematology Injections Insulin aspart 03 medical and health sciences 0302 clinical medicine Endocrinology Diabetes management Internal medicine Insulina Post-hoc analysis Internal Medicine medicine Humans Hypoglycemic Agents Patient Reported Outcome Measures basal insulin Insulin glargine Cumulative dose Liraglutide business.industry Original Articles Insulin Long-Acting GLP‐1RA analogue Regimen Drug Combinations Diabetes mellitus tipo 2 Diabetes Mellitus Type 2 Original Article type 2 diabetes Factores de riesgo de enfermedad cardiaca business medicine.drug |
| Zdroj: | ABACUS. Repositorio de Producción Científica Universidad Europea (UEM) Diabetes, Obesity & Metabolism |
| Popis: | Aims: Basal-bolus therapy is associated with greater treatment burden and lower adherence compared with more simplified regimens. This post hoc analysis studied the difference between insulin degludec/liraglutide (IDegLira) and basal-bolus therapy on number of injections, dose adjustments and patient outcomes in the DUAL VII trial. Materials and methods: DUAL VII was a 26-week, open-label trial in which patients with uncontrolled type 2 diabetes who were using metformin and insulin glargine 100 units/mL (20-50 U) were randomized 1:1 to IDegLira (N = 252) or basal-bolus (insulin glargine U100 + insulin aspart ≤4 times/day) (N = 254). This post hoc analysis reports the observed mean number of injections and cumulative dose adjustments during 26 weeks of treatment. Patient-reported outcomes (Treatment-Related Impact Measure - Diabetes [TRIM-D] and Short Form-36 Health Survey version 2 [SF-36v2]) were collected at scheduled visits and change from baseline scores calculated. Results: The clinical benefits (non-inferior HbA1c reductions, weight benefit, less hypoglycaemia) of IDegLira vs basal-bolus therapy were achieved with fewer cumulative dose adjustments (16.6 vs 217.2, respectively) and fewer injections (1 vs ≥3 per day, respectively). Patients treated with IDegLira experienced significant improvements across all TRIM-D domains compared with those undergoing basal-bolus therapy. The SF-36v2 showed improvements in both treatment arms with no significant difference between arms in the physical component summary, but there was a significant improvement in patients treated with IDegLira in the mental component summary (P = .0228). Conclusions: These findings, combined with the DUAL VII results, suggest that IDegLira, through a more simplified regimen versus basal-bolus therapy, may help improve patient adherence and improve patient outcomes related to diabetes management, treatment burden and mental health, which in turn may assist in the timely achievement of glycaemic control in clinical practice. Sin financiación 5.900 JCR (2019) Q1, 18/143 Endocrinology & Metabolism 2.497 SJR (2019) Q1, 7/132 Endocrinology No data IDR 2019 UEM |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|